You are here
Home > YELIVA™

RedHill Biopharma Announces Initiation of Phase II Study with YELIVA™ in Hepatocellular Carcinoma at the Medical University of South Carolina

The Phase II clinical study is intended to evaluate the efficacy and safety of YELIVA™ (ABC294640) in patients with advanced hepatocellular carcinoma (HCC), the most common primary malignant cancer of the liver with a worldwide mortality rate of 95% The Phase II study is being conducted at the Hollings Cancer Center at the Medical University […]

RedHill Biopharma Announces Research Collaboration with Stanford University for YELIVA™

TEL-AVIV, Israel, Sept. 12, 2016 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced a research collaboration with Stanford University School of Medicine (“Stanford”) for the […]